Literature DB >> 27001055

[Current therapy of polyarticular forms of juvenile idiopathic arthritis].

A Hospach1, J M Rühlmann2, F Weller-Heinemann3.   

Abstract

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in infancy and childhood. Approximately 20 % of patients with JIA suffer from the polyarticular form of the disease, which causes a substantial disease burden and long-term sequelae. Therapeutic approaches have used steroids and conventional disease modifying antirheumatic drugs (DMARD) but over the last decade new drugs have become available for the treatment of JIA, in particular biologic DMARD. This article summarizes the current therapy options for polyarticular JIA.

Entities:  

Keywords:  Biologics; Disease modifying antirheumatic drugs; Juvenile idiopathic arthritis; Polyarthritis; Therapy

Mesh:

Substances:

Year:  2016        PMID: 27001055     DOI: 10.1007/s00393-016-0063-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  54 in total

1.  The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.

Authors:  Dirk Holzinger; Michael Frosch; Astrid Kastrup; Femke H M Prince; Marieke H Otten; Lisette W A Van Suijlekom-Smit; Rebecca ten Cate; Esther P A H Hoppenreijs; Sandra Hansmann; Halima Moncrieffe; Simona Ursu; Lucy R Wedderburn; Johannes Roth; Dirk Foell; Helmut Wittkowski
Journal:  Ann Rheum Dis       Date:  2012-01-20       Impact factor: 19.103

2.  Recommendations for juvenile idiopathic arthritis by the American College of Rheumatology: comment on the article by Beukelman et al.

Authors:  Hans-Iko Huppertz
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-09       Impact factor: 4.794

3.  Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study.

Authors:  K Kotaniemi; H Kautiainen; A Karma; K Aho
Journal:  Ophthalmology       Date:  2001-11       Impact factor: 12.079

4.  Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations.

Authors:  Kiem Oen; Peter N Malleson; David A Cabral; Alan M Rosenberg; Ross E Petty; Martin Reed; Marlis L Schroeder; Mary Cheang
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

5.  Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.

Authors:  Jeffrey R Curtis; Theresa McVie; Ted R Mikuls; Richard J Reynolds; Iris Navarro-Millán; James O'Dell; Larry W Moreland; S Louis Bridges; Veena K Ranganath; Stacey S Cofield
Journal:  J Rheumatol       Date:  2013-04-15       Impact factor: 4.666

6.  A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.

Authors:  Nicolino Ruperto; Kevin J Murray; Valeria Gerloni; Nico Wulffraat; Sheila Knupp Feitosa de Oliveira; Fernanda Falcini; Pavla Dolezalova; Maria Alessio; Ruben Burgos-Vargas; Fabrizia Corona; Richard Vesely; Helen Foster; Joyce Davidson; Francesco Zulian; Line Asplin; Eileen Baildam; Julia Garcia Consuegra; Huri Ozdogan; Rotraud Saurenmann; Rik Joos; Angela Pistorio; Pat Woo; Alberto Martini
Journal:  Arthritis Rheum       Date:  2004-07

7.  Course, complications, and outcome of juvenile arthritis-related uveitis.

Authors:  Kourosh Sabri; Rotraud K Saurenmann; Earl D Silverman; Alex V Levin
Journal:  J AAPOS       Date:  2008-09-12       Impact factor: 1.220

8.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

9.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Authors:  Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

10.  Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past.

Authors:  Hans-Iko Huppertz; Dirk Föll; Hermann Girschick; Kirsten Minden; Gerd Horneff
Journal:  Rheumatol Int       Date:  2011-09-08       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.